3L+ metastatic colorectal cancer (RAS/B-Rapidly Accelerated Fibrosarcoma (BRAF) wild type)
BCAXBicara TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for Ficerafusp alfa -/+ Pembrolizumab in 3L+ metastatic colorectal cancer (RAS/B-Rapidly Accelerated Fibrosarcoma (BRAF) wild type). The expected timing is based on the latest available company guidance and may change.
5/13/25- Initiate trial in 2025. 11/10/25:- Phase 1b colorectal cancer cohort enrolling; data from monotherapy/combination expected in 2026. 01/12/26:- Phase 1b mCRC expansion cohort mono/combination data planned in H2 2026. 03/30/26:- Phase 1b 3L+ mCRC expansion cohort ongoing; data presentation planned in H2 2026. 05/11/26:- Plan H2 2026 data from Ph1b 3L+ mCRC mono/combination expansion cohort. 08/11/26:- Phase 1b 3L+ mCRC monotherapy and combination expansion-cohort data will be presented in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.